A Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KX2-361 in Subjects With Advanced Malignancies That Are Refractory to Conventional Therapies

Trial Profile

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KX2-361 in Subjects With Advanced Malignancies That Are Refractory to Conventional Therapies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2016

At a glance

  • Drugs KX 02 (Primary)
  • Indications Brain metastases; Cancer; Glioma
  • Focus Adverse reactions; First in man
  • Sponsors Athenex
  • Most Recent Events

    • 16 Nov 2016 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017.
    • 16 Nov 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
    • 30 Dec 2014 New source identified and integrated: ClinicalTrials.gov (NCT02326441).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top